Skip to content

Repligen RGEN Share Buybacks

Share Buybacks at other companies

TEC
Bio-TechneTECH
$24K
Revvity logo
RevvityRVTY
$86.5M-43.7%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3B+50.0%
Danaher logo
DanaherDHR
$0-100%
Agilent Technologies logo
Agilent TechnologiesA
$65M-60.6%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$47.8M-53.1%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Repligen’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's share buybacks?
Repligen (RGEN) reported share buybacks of $0 in Q4 2025.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.